Bill Text: CA SB706 | 2019-2020 | Regular Session | Enrolled
Bill Title: Public health: pulmonary hypertension task force.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Vetoed) 2020-01-13 - Veto sustained. [SB706 Detail]
Download: California-2019-SB706-Enrolled.html
|
Enrolled
September 12, 2019 |
|
Passed
IN
Senate
September 10, 2019 |
|
Passed
IN
Assembly
September 09, 2019 |
|
Amended
IN
Assembly
September 03, 2019 |
|
Amended
IN
Assembly
July 01, 2019 |
|
Amended
IN
Senate
April 29, 2019 |
|
Amended
IN
Senate
March 27, 2019 |
CALIFORNIA LEGISLATURE—
2019–2020 REGULAR SESSION
Senate Bill
No. 706
| Introduced by Senator Galgiani |
February 22, 2019 |
An act to add and repeal Section 104101 of the Health and Safety Code, relating to public health.
LEGISLATIVE COUNSEL'S DIGEST
SB 706, Galgiani.
Public health: pulmonary hypertension task force.
Existing law requires the State Department of Public Health to conduct a program for the control of high blood pressure, also known as hypertension and that includes pulmonary hypertension.
This bill would require the department to establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, as specified. The bill would specify the composition and duties of the task force, including developing and updating a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pulmonary hypertension, including pediatric pulmonary hypertension. The bill would require the task force to submit a report to the Governor’s office and the Legislature on or before January 1, 2021, and again on or before January 1,
2023, and would repeal these provisions on January 1, 2023.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NOBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 104101 is added to the Health and Safety Code, to read:104101.
(a) The department shall establish a pulmonary hypertension task force for the purpose of aggregating and disseminating the latest information and research relating to pulmonary hypertension, including pediatric pulmonary hypertension.(b) The task force shall do all of the following:
(1) Develop and update a summary of the advances made in research on, and treatment and diagnosis of, pulmonary hypertension, including pediatric pulmonary hypertension.
(2) Develop and update a summary of the advances made in access to care for individuals with a
diagnosis of pulmonary hypertension, including pediatric pulmonary hypertension.
(3) Monitor pulmonary hypertension, including pediatric pulmonary hypertension, research, services, and support activities across the state, including coordination of the state’s activities and programs with respect to pulmonary hypertension, including pediatric pulmonary hypertension.
(4) Develop and update a comprehensive strategic plan to improve health outcomes for individuals with a diagnosis of pulmonary hypertension, including pediatric pulmonary hypertension, including recommendations on how to do all of the following:
(A) Advance research on pulmonary hypertension, including pediatric pulmonary hypertension.
(B) Improve the transplantation criteria and process concerning both lung transplants and heart and lung transplants for individuals with a diagnosis of pulmonary hypertension.
(C) Improve public awareness and recognition of pulmonary hypertension, including pediatric pulmonary hypertension.
(D) Improve health care delivery for individuals with a diagnosis of pulmonary hypertension, including pediatric pulmonary hypertension.
(E) Improve the early and accurate diagnosis of pulmonary hypertension, including pediatric pulmonary hypertension.
(F) Systematically advance the full spectrum of biomedical research
on pulmonary hypertension, including pediatric pulmonary hypertension.
(5) Develop and update the progress made in implementing the comprehensive strategic plan developed pursuant to paragraph (4).
(c) The task force shall be composed of the following members:
(1) The Secretary of California Health and Human Services or a designee, who shall serve as the chair of the task force.
(2) The State Public Health Officer or a designee.
(3) The Insurance Commissioner or a designee.
(4) The Director of the Department of Managed Health Care or a designee.
(5) The Director of Health Care Services or a designee.
(6) Nine additional members to be appointed by the secretary as follows:
(A) Three health care providers, including at least one physician and one cardiologist, who care for individuals with pulmonary hypertension or pediatric pulmonary hypertension.
(B) Two representatives from a commercial health insurance plan or managed care organization operating in the state.
(C) One individual with a diagnosis of pulmonary hypertension or the parent or guardian of an individual with a diagnosis of
pediatric pulmonary hypertension.
(D) One representative of a pharmaceutical company that manufactures a drug or device for detecting, preventing, or treating pulmonary hypertension.
(E) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pediatric pulmonary hypertension.
(F) One representative of a research, advocacy, or support organization primarily serving individuals with a diagnosis of pulmonary hypertension.
(d) Members of the task force shall serve without compensation. All administrative requirements for the production of the reports shall be completed by the
California Health and Human Services Agency.
(e) The task force shall submit a report to the Governor’s office and the Legislature on or before January 1, 2021, and again on or before January 1, 2023. The reports shall be submitted in compliance with Section 9795 of the Government Code.
(f) This section shall remain in effect only until January 1, 2023, and as of that date is repealed.
